VANCOUVER, May 1 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced
today that David A. Saperstein, M.D. will be joining QLT as a consultant and
interim Chief Medical Officer and Paul L. Kaufman, M.D. as Head of our Ocular
Scientific Advisory Board.
"We are very pleased to be able to attract these internationally highly
regarded experts in ophthalmology to help us assess and develop new treatments
for ocular diseases," said Bob Butchofsky, President and Chief Executive
Officer of QLT Inc. "Dr. Kaufman is a world-renowned expert in glaucoma and
Dr. Saperstein is a highly respected vitreo-retinal clinician and surgeon
bringing a wealth of experience in both academic and private practice. We are
extremely pleased that Paul and David have agreed to join us in order to apply
their collective experience to help QLT develop new products to treat ocular
QLT will host its inaugural Ocular Scientific Advisory Board meeting
under Dr. Kaufman's leadership early May.
QLT is building on a relationship established with Dr. Saperstein over
several years, starting with his role as one of the original investigators who
helped to get Visudyne approved in the U.S. and more recently in his role as
one of the co-founders of Retinagenix. In early 2006, QLT entered into an
exclusive worldwide co-development and licensing agreement with Retinagenix,
LLC, to develop active synthetic retinoid products for the treatment of
degenerative retinal diseases.
David A. Saperstein, M.D., is a retinal specialist practicing at
Vitreoretinal Associates and an active medical staff at Swedish Hospital in
Seattle, Washington. Dr. Saperstein specializes in the medical and surgical
treatment of retinal diseases and has a special interest in the treatment of
age-related macular degeneration (AMD), diabetic retinopathy, surgical
diseases of the retina and the management of ocular trauma. Dr. Saperstein
actively participates in clinical trials for the treatment of AMD; he has had
continuous and ongoing research funding, has authored several peer reviewed
articles, published abstracts and six book chapters, and also received a
number of honors and awards. Dr. Saperstein has also held a number of Faculty
positions including Assistant Professor, Department of Ophthalmology, Emory
University and Associate Professor, Department Ophthalmology, University of
Washington. Dr. Saperstein attended medical school at Pennsylvania State
University in Hershey, Pennsylvania after completing his B.S. Electrical
Engineering with honors at George Washington University.
Paul L. Kaufman, M.D., is Professor and Chair of the Department of
Ophthalmology & Visual Sciences at the University of Wisconsin Medical School,
in Madison, Wisconsin. He is a physician-scientist, specializing in glaucoma
and studying the mechanisms of aqueous humor formation and drainage, and the
age-related loss of near vision (presbyopia). Dr. Kaufman is a past President
and current Executive Vice President of the Association for Research in Vision
and Ophthalmology (ARVO), past President of the International Society for Eye
Research, and has served on the US National Advisory Eye Council and numerous
foundation and corporate scientific advisory boards. He has had continuous
research funding from the US National Eye Institute for 27 years, has authored
over 300 original scientific articles and 50 book chapters, co-edited several
textbooks including the most recent edition of Adler's Physiology of the Eye,
and received numerous honors and awards. Dr. Kaufman attended medical school
at New York School of Medicine after completing his undergraduate education in
QLT Inc. is a global biopharmaceutical company dedicated to the
discovery, development and commercialization of innovative therapies. Our
research and development efforts are focused on pharmaceutical products in the
fields of ophthalmology and dermatology. In addition, we utilize two unique
technology platforms, photodynamic therapy and Atrigel(R), to create products
such as Visudyne(R) and Eligard(R). For more information, visit our web site
Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol
"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
Certain statements in this press release which are not historical facts,
are "forward-looking" statements as the term is defined in the United States
Private Securities Litigation Reform Act of 1995, and "forward-looking
information" within the meaning of applicable Canadian Securities legislation.
You can identify these forward-looking statements and information by QLT's use
of words such as "expects," "plans," "estimates," "projects," "intends,"
"believes," and similar expressions that do not relate to historical matters.
Such forward-looking statements and information are subject to risks and
uncertainties which can cause actual results to differ materially from those
currently anticipated, due to a number of factors. These statements include
the risk that we may not be able to implement our strategic goals. Factors
that could cause such actual events or results expressed or implied by such
forward-looking statements to differ materially from any future results
expressed or implied by such statements are described in detail in QLT's
Annual Information Form on Form 10-K, quarterly reports on Form 10-Q and other
filings with the U.S. Securities and Exchange Commission and Canadian
securities regulatory authorities. Forward-looking statements are based on our
current expectations and QLT does not assume any obligation to update such
information to reflect later events or developments, except as may be required
For further information:
For further information: QLT Inc.: Vancouver, Canada, Tamara Hicks,
Telephone: (604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001